Printer Friendly

Successful treatment of chronic vaginitis: arm yourself with these best options for tackling insistent infection.

Gadzooks! In preparing for the morning office practice session you notice that two patients with chronic vaginitis have been scheduled back to back in 15-minute slots.

Ms. A has chronic bacterial vaginosis. Ms. B has chronic yeast vaginitis. What are you going to do?

Chronic bacterial vaginosis

The normal vaginal microbiome is dominated by Lactobacillus crispatus and Lactobacillus jensenii. These organisms produce hydrogen peroxide and keep the vaginal pH [less than equal to] 4.5. When Gardnerella vaginalis and associated anaerobic bacteria gain dominance in the vagina, bacterial vaginosis ensues. This infection is characterized by (1):

* homogenous, thin, grayish-white discharge that smoothly coats the vaginal epithelium

* pH >4.5

* fishy odor when potassium hydroxide is added to a sample of the discharge

* clue cells on a saline wet mount.

Why is it prone to recur? If bacterial vaginosis was a simple infection, treatment with metronidazole or clindamycin should be very effective. But in many women the relief from symptoms provided by a single course of antibiotics is short-lived, and many patients experience recurrent bacterial vaginosis in the next few months.

The cause of this resistance to antibiotic treatment may be that G vaginalis and other anaerobes, such as Atopobium species, aggregate in vaginal biofilms that prevent the antibiotic from reaching the organism. (2) The biofilm provides a safe haven for the bacteria to regrow following a single course of treatment? In addition, the nutrient-limited environment inside the encapsulated biofilm helps the bacteria to resist the toxic effects of the antibiotic. (4)

Another potential mechanism for bacterial vaginosis recurrence is that women destined to develop repeat infection often harbor Guaginalis encapsulated in biofilms in the mouth. These extravaginal bacteria often are found again in the vagina, suggesting that bacterial vaginosis can be acquired from extravaginal bacterial reservoirs. (5) Investigators are developing approaches, such as intravaginal treatment with DNase, to destroy the vaginal biofilm in order to enhance the efficacy of antibiotic treatment. (6)


Options for initial infection. There are three treatments for an initial occurrence of bacterial vaginosis (7):

* oral metronidazole 500 mg twice daily for 7 days

* 0.75% metronidazole gel one applicator intravaginally once daily for 5 days, or

* 2% clindamycin cream one applicator intravaginally at bedtime for 7 days.

Long-term metronidazole for recurrence. Approximately half of women who respond to initial treatment will have bacterial vaginosis again within 1 year. If vaginitis caused by recurrent bacterial vaginosis is diagnosed, a prolonged course of antibiotic treatment is warranted. Treatment starts with an induction regimen of the standard treatments listed in the paragraph above. This is followed by a long-term maintenance regimen using 0.75% metronidazole vaginal gel one applicator twice weekly for 4 to 6 months. (8)

Recurrent Candida vulvovaginitis

Four or more occurrences of symptomatic Candida vulvovaginitis in 12 months indicates recurrent infection. Recurrence is usually caused by reinfection with the same organism from a vaginal reservoir. For women with such repeat infection, vaginal cultures should be obtained to confirm Candida and to search for treatment-resistant species, such as Candida glabrata. (Many C glabrata organisms are resistant to standard fluconazole treatment.)

Treatment options

Long courses of oral or vaginal antimycotic agents can be effective treatment for recurrent Candida vulvovaginitis.

Fluconazole. One regimen is fluconazole 150 mg orally every 72 hours for 3 doses, followed by fluconazole 150 mg once weekly for 6 months. (9) If patients relapse from this regimen, then the vaginitis should be retreated with fluconazole 150 mg orally every 72 hours for 3 doses, followed by fluconazole 150 mg weekly for 12 months.

Boric acid. If C glabrata is thought to be the cause of the infection, it may be difficult to eradicate with fluconazole. A regimen to treat recurrent vaginitis caused by C glabrata is intravaginal boric acid, a 600 mg capsule once nightly for 14 days. (10,11) This medication is not FDA-approved for this purpose and must be made by a compounding pharmacy. Boric acid can be fatal if swallowed rather than used intravaginally. Care must be taken to avoid access to these capsules by children.

Boric acid vaginal capsules also can be used to treat chronic bacterial vaginosis in combination with antibiotic therapy. (12)

Flucytosine. An alternative regimen to treat C glabrata is flucytosine vaginal cream one applicator nightly for 14 days. This vaginal cream must be compounded because it is not available as a commercial medication.

You are armed and ready

In retrospect, you realize that the morning office session schedule is going to be fine. You will treat Ms. A with a long course of metronidazole and Ms. B with a long course of fluconazole. Hopefully, they will both find relief from their symptoms.

Instant Poll

What are your greatest clinical successes with the treatment of chronic bacterial vaginosis or chronic Candida vaginitis that you would like to share with our readers, your ObGyn colleagues?

Tell us--at

rbarbieri@frontlinemedcom. com. Please include your name and city and state.


(1.) Eschenbach DA, Hillier S, Critchlow C, Stevens C, DeRouen T, Holmes KK. Diagnosis and clinical manifestations of bacterial vaginosis. Am J Obstet Gynecol. 1988;158(4):819-828.

(2.) Swidinski A, Mendling W, Loening-Baucke V, et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol. 2005; 106(5 pt 1):1013-1023.

(3.) Swidinski A, Mendling W, Loening-Baucke V, et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol. 2008;198(1):97el-e6.

(4.) Monds RD, O'Toole GA. The developmental model of microbial biofilm: ten years of a paradigm up for review. Trends Microbiol. 2009;17(2):73-87.

(5.) Marrazzo JM, Friedler TL, Srinivasan S, et al. Extravaginal reservoirs of vaginal bacteria as risk factors for incident bacterial vaginosis. J Infect Dis. 2012;205(10): 1580-1588.

(6.) Hymes SR, Randis TM, Sun TY, Ratner AJ. DNase inhibits Gardnerella vaginalis biofilms in vitro and in vivo. J Infect Dis. 2013;207(10):1491-1497.

(7.) Workowski KA, Berman S; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010; 59(RR-12):1-110.

(8.) Sobel JD, Ferris D, Schwebke J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol. 2006;194(5): 1283-1289.

(9.) Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med. 2004;351(9):876-883.

(10.) Savini V, Catavitello C, Bianco A, Balbinot A, D'Antonio F, D'Antonio D. Azole resistant Candida glabrata vulvovaginitis treated with boric acid. Eur J Obstet Gynecol Reprod Biol. 2009;147(1):112.

(11.) Iavazzo C, Gkegkes ID, Zarkada IM, Falagas ME. Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. J Womens Health (Larchmt). 2011;20(8):1245-1255.

(12.) Reichman O, Akins R, Sobel JD. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex Transm Dis. 2009;36(11):732-734.

Robert L. Barbieri, MD Editor in Chief


Dr. Barbieri reports no financial relationships relevant to this article.
COPYRIGHT 2013 Quadrant Healthcom, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Editorial
Author:Barbieri, Robert L.
Publication:OBG Management
Article Type:Disease/Disorder overview
Date:Jul 1, 2013
Previous Article:14 months' recovery after mass removed.
Next Article:What about very young sexually active women?

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters